12 days ago
SEPN
AnalystsSrikripa DevarakondaSrikripa Devarakonda's Stock Forecasts
AnalystsSrikripa Devarakonda
Analyst Ranking
Top 12%
#616 out of 5223 analysts
Average Return
+13.88%
Win Rate
51%42 out of 82
Risk vs Reward
Poor
Good
Srikripa Devarakonda's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | +469.88% | $8.50 | $48.44 | 2025-10-15 - 2026-03-20 | Strong Buy |
Verastem IncVSTM | +229.72% | $2.49 | $8.21 | 2024-08-13 - 2025-08-12 | Strong Buy |
Terns Pharmaceuticals IncTERN | +177.91% | $17.43 | $48.44 | 2025-11-04 - 2026-03-20 | Strong Buy |
Edgewise Therapeutics IncEWTX | +131.48% | $7.56 | $17.50 | 2023-06-28 - 2024-06-27 | Strong Buy |
Scholar Rock Holding CorpSRRK | +113.66% | $15.23 | $32.54 | 2024-04-03 - 2025-04-02 | Strong Buy |
Srikripa Devarakonda Analyst Color
Get additional color on Srikripa Devarakonda's coverage of popular stocks
19 days ago
SRRK
2 months ago
CYTK
3 months ago
PTGX
3 months ago
KYMR
4 months ago
KYMR
4 months ago
MDGL
a year ago
LLY
a year ago
PFE
a year ago
EWTX
a year ago
SRRK
a year ago
LLY
2 years ago
LLY
2 years ago
LLY
2 years ago
KYMR
Srikripa Devarakonda's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Inventiva SaIVA | 1 | Strong Buy | $13.00 | +124.91% | Initiates Coverage On | 4 days ago |
Septerna IncSEPN | 2 | Strong Buy | $35.00 | +44.75% | Maintains | 12 days ago |
Scholar Rock Holding CorpSRRK | 6 | Strong Buy | $55.00 | +23.21% | Maintains | 19 days ago |
Biogen IncBIIB | 6 | Hold | $193.00 | +6.36% | Maintains | a month ago |
Cytokinetics IncCYTK | 5 | Strong Buy | $92.00 | +49.11% | Maintains | 2 months ago |
Protagonist Therapeutics IncPTGX | 4 | Strong Buy | $110.00 | +11.26% | Maintains | 3 months ago |
Kymera Therapeutics IncKYMR | 6 | Strong Buy | $116.00 | +48.89% | Maintains | 3 months ago |
Terns Pharmaceuticals IncTERN | 4 | Strong Buy | $56.00 | +15.61% | Maintains | 3 months ago |
Madrigal Pharmaceuticals IncMDGL | 2 | Strong Buy | $640.00 | +45.07% | Maintains | 4 months ago |
Incyte CorpINCY | 12 | Hold | $93.00 | +2.45% | Reiterates | 5 months ago |
Viatris IncVTRS | 1 | Strong Buy | $15.00 | +13.64% | Initiates Coverage On | 5 months ago |
Mbx Biosciences IncMBX | 1 | Strong Buy | $50.00 | +74.34% | Initiates Coverage On | 5 months ago |
Regeneron Pharmaceuticals IncREGN | 8 | Strong Buy | $812.00 | +10.80% | Maintains | 7 months ago |
Arvinas IncARVN | 1 | Hold | $11.00 | +0.55% | Downgrades | a year ago |
Keros Therapeutics IncKROS | 5 | Strong Buy | $25.00 | +128.10% | Maintains | a year ago |
Eli Lilly & CoLLY | 4 | Strong Buy | $1,038.00 | N/A | Maintains | a year ago |
Abbvie IncABBV | 3 | Strong Buy | $217.00 | N/A | Maintains | a year ago |
Pfizer IncPFE | 1 | Strong Buy | $32.00 | N/A | Maintains | a year ago |
Edgewise Therapeutics IncEWTX | 6 | Strong Buy | $50.00 | N/A | Maintains | a year ago |
Biomea Fusion IncBMEA | 1 | Strong Buy | $54.00 | N/A | Upgrades | a year ago |
Verastem IncVSTM | 7 | Strong Buy | $15.00 | N/A | Maintains | 2 years ago |
Nurix Therapeutics IncNRIX | 1 | Strong Buy | $36.00 | N/A | Initiates Coverage On | 2 years ago |
Affimed NvAFMDQ | 2 | Strong Buy | $60.00 | N/A | Maintains | 3 years ago |
9 Meters Biopharma IncNMTRQ | 3 | Hold | $38.00 | N/A | Downgrades | 3 years ago |
Constellation Pharmaceuticals IncCNST | 2 | Hold | $34.00 | N/A | Downgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.